Campbell & CO Investment Adviser LLC
Position in KALV — KalVista Pharmaceuticals, Inc.
CIK 1353570
BALTIMORE, MD
Position in KALV
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,293,332
+$992,683 QoQ
Shares Held
64,249
+151.7% QoQ
Ownership
0.121%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#70
of 182 holders
Holding Since
Dec 2023
4 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in KALV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Campbell & CO Investment Adviser LLC holds $45,287,811 across 43 Biotechnology names. KALV ranks #11 (2.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
9,034 | $6,597,078 | |
| 2 | KRYS |
Krystal Biotech, Inc.
|
17,795 | $4,596,804 | |
| 3 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
83,617 | $3,036,969 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
29,130 | $2,832,892 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,580 | $2,491,693 | |
| 6 | TECH |
BIO-TECHNE Corp
|
41,339 | $2,160,376 | |
| 7 | RPRX |
Royalty Pharma plc
|
31,202 | $1,496,759 | |
| 8 | PRTA |
Prothena Corp Public Ltd Co
|
142,587 | $1,385,945 |
All Filings in KALV
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,293,332 | 64,249 | Shares | Sole | 2026-05-15 | |
| 2024-06-30 | $300,649 | 25,522 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $118,647 | 10,004 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $506,721 | 41,365 | Shares | Sole | 2024-02-13 | |
| No filing history on record for this holder in this stock. | ||||||